Literature DB >> 773180

Beta-lactam antibiotics alone or in combination with gentamicin for therapy of gram-negative bacillary infections in neutropenic patients.

G P Bodey, R Feld, M A Burgess.   

Abstract

This study was initiated to determine whether antibiotic combinations are superior to single antibiotics for the treatment of gram-negative bacillary infections in neutropenic patients. Twenty-six patients with Pseudomonas and Proteus infections received either carbenicillin or carbenicillin, plus gentamicin. The cure rates were 83 and 93 per cent, respectively. Twenty-three patients with infections caused by other gram-negative bacilli received either cephalothin plus gentamicin. The cure rates were 64 and 67 per cent, respectively. Superinfection occurred in 26 per cent of the patients who received a single antibiotic compared to 15 per cent of the patients who received a combination. Four of the 26 patients who received gentamicin developed transient azotemia. Combination therapy may be superior to single antibiotic therapy, but this study demonstrated no statistically significant differences.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 773180     DOI: 10.1097/00000441-197603000-00006

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  13 in total

Review 1.  Antimicrobial agent therapy for Pseudomonas aeruginosa.

Authors:  J A Korvick; V L Yu
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

Review 2.  Clinical and economic considerations of empirical antibacterial therapy of febrile neutropenia in cancer.

Authors:  G Dranitsaris
Journal:  Pharmacoeconomics       Date:  1999-10       Impact factor: 4.981

3.  A review of patents (2011-2015) towards combating resistance to and toxicity of aminoglycosides.

Authors:  Nishad Thamban Chandrika; Sylvie Garneau-Tsodikova
Journal:  Medchemcomm       Date:  2015-11-19       Impact factor: 3.597

4.  In vitro synergistic activities of tobramycin and selected beta-lactams against 75 gram-negative clinical isolates.

Authors:  R C Owens; M A Banevicius; D P Nicolau; C H Nightingale; R Quintiliani
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

5.  Unpredictable response of Pseudomonas aeruginosa to synergistic antibiotic combinations in vitro.

Authors:  H S Heineman; W M Lofton
Journal:  Antimicrob Agents Chemother       Date:  1978-05       Impact factor: 5.191

Review 6.  Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis.

Authors:  Mical Paul; Adi Lador; Simona Grozinsky-Glasberg; Leonard Leibovici
Journal:  Cochrane Database Syst Rev       Date:  2014-01-07

7.  Bactericidal activity of ceftazidime in serum compared with that of ticarcillin combined with amikacin.

Authors:  H C Standiford; G L Drusano; B Fitzpatrick; B Tatem; S C Schimpff
Journal:  Antimicrob Agents Chemother       Date:  1984-09       Impact factor: 5.191

8.  Comparison of azlocillin, ceftizoxime, cefoxitin, and amikacin alone and in combination against Pseudomonas aeruginosa in a neutropenic-site rabbit model.

Authors:  L R Peterson; D N Gerding; J A Moody; C E Fasching
Journal:  Antimicrob Agents Chemother       Date:  1984-05       Impact factor: 5.191

9.  Mezlocillin for treatment of infections in cancer patients.

Authors:  B F Issell; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1980-06       Impact factor: 5.191

10.  Comparative in vitro study of teichomycin A2.

Authors:  V Fainstein; B LeBlanc; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1983-03       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.